Ziptek is the only company in the world that can maximize the tissue healing area for surgical repair while permitting the tissue to take over the load of the healing process from the repair device and maximizes repair tissue protection from damage.
The reason these Ziptek tissue healing advantages matter is that they could dramatically improve soft tissue injury surgeries that are performed every year around the world, at a cost of ~$48 billion.
Assuming Ziptek captured 10% of this tissue repair market, then Ziptek would generate $420 million in annual revenue, with approximate 20% operating profit margins which will increase with time.
Capturing and ultimately dominating this market is the reason Ziptek is currently seeking $5-10 million in growth capital.